Eli Lilly | LLY - Gross Profit On Sales



Eli Lilly reported $13.11B in Gross Profit on Sales for its fiscal quarter ending in June of 2025.


Gross Profit On Sales Change Date
AbbVie USD 9.34B 1.36B Mar/2025
Abbott USD 5.87B 50M Jun/2025
ALKERMES USD 257.77M 462K Jun/2025
Amgen USD 6.17B 624M Jun/2025
AstraZeneca USD 11.98B 637M Jun/2025
Baxter International USD 1.14B 283M Jun/2025
Biogen USD 2.04B 238.8M Jun/2025
Bristol-Myers Squibb USD 8.9B 714M Jun/2025
Drreddys Laboratories INR 48.63B 425M Jun/2025
Eli Lilly USD 13.11B 2.61B Jun/2025
Gilead Sciences USD 5.58B 453M Jun/2025
GlaxoSmithKline GBP 5.82B 229M Jun/2025
Glaxosmithkline GBP 5.83B 232M Jun/2025
J&J USD 14.6B 816M Mar/2025
Medtronic USD 5.12B 695M Jul/2025
Merck USD 12.99B 224M Jun/2025
Neurocrine Biosciences USD 676.2M 112.8M Jun/2025
Novartis USD 11.51B 1.12B Jun/2025
Novartis USD 11.52B 1.27B Jun/2025
Novo Nordisk 64.01B 1.19B Jun/2025
Perrigo USD 362.9M 29.4M Jun/2025
Pfizer USD 10.88B 248M Jun/2025
Prestige Brands USD 140.33M 29.68M Jun/2025
Regeneron Pharmaceuticals USD 3.15B 581M Jun/2025
Roche Holding CHF 11.69B 48M Dec/2024
Sanofi EUR 7.74B 26M Jun/2025
Sanofi EUR 7.74B 2.38B Jun/2025
United Therapeutics USD 711M 9.1M Jun/2025
Zoetis USD 1.78B 180M Jun/2025